Why Guanine Scales Differently
Most diagnostic platforms are constrained by hardware physics—optics, channels, lasers, and modality-specific instruments that limit multiplexing, slow innovation, and inflate capital requirements.
Guanine replaces those constraints with a software-defined electrochemical sensing architecture.
Our platform decouples diagnostic scale from hardware complexity, enabling rapid expansion across assays, markets, and partners without rebuilding instruments.
WHAT “SOFTWARE-DEFINED” MEANS AT GUANINE
-
Multiplexing is defined in software
Target identity, panel composition, and scale are encoded algorithmically—not limited by optical channels or physical detectors. -
One sensing layer, many configurations
The same electrochemical infrastructure supports nucleic acids, proteins, metabolites, cells, and redox chemistry from a single sample. -
OEM rehosting without hardware redesign
Diagnostic partners deploy proprietary biomarkers by configuring software, rather than building new instruments or assay-specific hardware. -
Low capital, fast deployment
New diagnostic applications are launched through configuration—not years of hardware development.
WHY THIS MATTERS FOR INVESTORS
-
Infrastructure economics
Each new diagnostic increases platform leverage without increasing platform complexity. -
Faster time to market
Software-driven configuration compresses development cycles from years to months. -
Multiple expansion paths
Sepsis is the first proof point—but the platform scales across acute care, pharmaceutical diagnostics, OEM partnerships, and multi-omic applications. -
Strategic optionality
Guanine is positioned as a foundational sensing layer for the next generation of diagnostics, not a single-product company.
BOTTOM LINE
Guanine is building the software-defined sensing infrastructure that diagnostics has historically lacked—unlocking speed, scale, and OEM-driven growth across the industry.
The Diagnostic Landscape Has Shifted—Permanently
Guanine is purpose-built for this new diagnostic reality.
Clinical Drivers
- Sepsis and AMR require rapid, actionable data
- Drug susceptibility must move beyond culture
- Clinicians need integrated host–pathogen-drug insight
Economic Drivers
- Hospitals face severe cost and staffing pressures
- Diagnostics must move closer to the patient and reduce system burden
OEM & Technology Drivers
- Optical platforms are hitting hard multiplexing limits
- AI requires high-plex, quantitative multi-omic data
- Precision health depends on high-plex, quantitative biomarker data at low cost